C-Peptide: What It Is and What It Tells You About Insulin

Key Takeaways

• What it measures: Endogenous insulin secretion; C-peptide is released in a one-to-one molar ratio with insulin during proinsulin processing in pancreatic beta cells.
• Typical reference range: Fasting serum: 0.5–2.0 ng/mL (0.17–0.83 nmol/L). Stimulated peak values are separately interpreted. Ranges vary by lab and assay.
• Sample type: Serum (standard fasting draw); urine C-peptide creatinine ratio (UCPCR) available as a non-invasive alternative in stable outpatients.
• Fasting required: Yes — 8–12 hours for a standard fasting serum measurement. Stimulated tests require provider-administered glucagon or mixed-meal protocol.
• When providers order it: Diabetes type classification, beta cell function monitoring, unexplained hypoglycemia workup, insulin treatment decision support.
• Test frequency: Varies by clinical context; may be repeated at intervals to monitor beta cell decline in Type 1, or at diagnosis and key decision points in Type 2.
• Key confounder: Renal impairment raises C-peptide levels because the kidney is the primary site of C-peptide clearance; results in patients with reduced kidney function should be interpreted with eGFR context.

What C-Peptide Is and What It Measures

C-peptide (connecting peptide) is a 31-amino-acid chain the pancreas releases in equal quantities alongside insulin during the processing of proinsulin. When pancreatic beta cells synthesize insulin, proinsulin — the precursor molecule — is cleaved into two parts: insulin itself and C-peptide. Both are released into the portal circulation in a one-to-one molar ratio. Because C-peptide is not taken up by the liver on first pass and has a longer half-life than insulin, blood C-peptide provides a more stable and accurate measure of how much insulin the body is actually making. A foundational review by Jones and Hattersley published in Diabetic Medicine in 2013 established C-peptide measurement as the primary clinical tool for assessing endogenous insulin secretion. Exogenous insulin injected for diabetes management contains no C-peptide, making C-peptide uniquely useful in people who use insulin therapy — it isolates the pancreas's own output without interference.

C-Peptide Reference Ranges

Reference values for serum C-peptide depend on whether the measurement is fasting or stimulated. Leighton and colleagues, in a 2017 practical review in Diabetes Therapy, describe the standard fasting and stimulated reference intervals used in clinical practice.

• Adults (fasting, serum) — reference interval: 0.5–2.0 ng/mL (0.17–0.83 nmol/L)
• Severely low or undetectable: Below approximately 0.2 nmol/L (0.6 ng/mL); associated with significant beta cell loss
• Elevated fasting: Above 2.0 ng/mL; associated with insulin resistance, hyperinsulinism, or early-to-moderate Type 2 diabetes
• Stimulated peak (glucagon or mixed-meal): Interpreted separately from fasting values; thresholds vary by protocol and clinical purpose
• Urine C-peptide creatinine ratio (UCPCR): Greater than 0.2 nmol/mmol generally indicates preserved beta cell function; below this threshold is associated with significant insulin deficiency

Reference ranges vary by laboratory and individual. The values above represent typical population-derived reference intervals and are not diagnostic thresholds. Your provider will interpret your specific result alongside symptoms, medical history, and other test findings.

What Causes High C-Peptide Levels

Elevated C-peptide indicates the pancreas is producing more insulin than expected. High levels do not always point to the most clinically significant cause — context and the full clinical picture matter considerably.

Insulin resistance and early Type 2 diabetes

In insulin resistance, the body requires more insulin to achieve normal blood glucose control. The pancreatic beta cells compensate by producing greater quantities of insulin — and therefore greater quantities of C-peptide. This compensatory hypersecretion is a hallmark of early-to-moderate Type 2 diabetes. Research by Lin and colleagues published in Diabetic Medicine in 2025 describes how C-peptide measurement captures this compensatory phase of Type 2 diabetes, providing additional information about beta cell function in adults with Type 2 diabetes. Elevated fasting C-peptide alongside elevated fasting insulin and glucose may indicate impaired insulin sensitivity before frank diabetes develops.

Obesity and metabolic syndrome

Excess adiposity — particularly visceral fat — is a driver of insulin resistance through inflammatory and hormonal mechanisms. In overweight and obese individuals, fasting C-peptide is frequently elevated relative to lean counterparts, reflecting increased insulin demand. Reintar and colleagues, writing in Nutrients in 2023, demonstrated that urinary C-peptide creatinine ratio correlates with metabolic risk indicators even in adults without diagnosed diabetes, suggesting C-peptide provides relevant signal across the metabolic health spectrum.

Insulinoma and sulfonylurea use

High C-peptide in the setting of low blood glucose — hypoglycemia — is a specific pattern that warrants clinical evaluation. An insulinoma (an insulin-secreting pancreatic tumor) produces endogenous insulin and C-peptide continuously, causing hypoglycemia with inappropriately high C-peptide levels. Sulfonylurea medications, which stimulate beta cell insulin release, produce a similar biochemical picture. Rubenstein and colleagues, in the classic 1977 paper in Archives of Internal Medicine, established the clinical utility of C-peptide for differentiating endogenous hyperinsulinism from exogenous insulin injection. This distinction relies on the fact that injected insulin contains no C-peptide, so factitious hypoglycemia from exogenous insulin produces low C-peptide with low glucose — the opposite of insulinoma.

What Causes Low C-Peptide Levels

Low C-peptide reflects reduced or absent insulin production from pancreatic beta cells. This is one of the most clinically consequential C-peptide findings, and it anchors major therapeutic decisions in diabetes care.

Type 1 diabetes and autoimmune beta cell destruction

In Type 1 diabetes, the immune system attacks and destroys pancreatic beta cells, progressively eliminating the capacity for endogenous insulin production. C-peptide levels fall over the years following diagnosis, reaching very low or undetectable values in most individuals with established Type 1 diabetes. Greenbaum and colleagues, in a longitudinal analysis published in Diabetes in 2012 tracking C-peptide in TrialNet participants, documented a two-phase fall in C-peptide during the first two years following Type 1 diagnosis. Davis and colleagues, publishing T1D Exchange data in Diabetes Care in 2015, quantified the fall in C-peptide across age at diagnosis and diabetes duration, demonstrating that the rate of loss varies between individuals and that residual C-peptide, even at low levels, carries clinical significance.

Late-stage Type 2 diabetes and beta cell exhaustion

In the natural history of Type 2 diabetes, sustained demand for excess insulin production can eventually exhaust beta cell function. Over years to decades, C-peptide levels that were initially elevated may decline to low or near-absent values, indicating the pancreas can no longer compensate. Lin and colleagues in 2025 describe how C-peptide monitoring in Type 2 diabetes helps identify this transition, which is the clinical trigger for moving from oral agents to insulin therapy. A low stimulated C-peptide in a patient with Type 2 diabetes supports the need for insulin, as documented by Lee and colleagues in a 1996 paper in Endocrine Practice examining stimulated C-peptide as a criterion for insulin treatment in adult-onset Type 2 diabetes.

Latent autoimmune diabetes in adults (LADA)

LADA presents as Type 2 diabetes clinically but involves autoimmune beta cell destruction similar to Type 1. C-peptide levels may be initially preserved in LADA but decline more rapidly than in true Type 2 diabetes. A comprehensive clinical review by Maddaloni and colleagues published in Diabetes, Obesity and Metabolism in 2022 details how C-peptide, combined with autoantibody testing, helps differentiate LADA from Type 2 diabetes — a distinction that can shape treatment decisions, including the timing of insulin initiation.

Factors That Affect C-Peptide Results

Several factors beyond diabetes type can shift C-peptide values up or down, sometimes meaningfully. Awareness of these confounders is essential for accurate interpretation.

• Renal impairment — raises levels: The kidney is the primary site of C-peptide clearance. Reduced kidney function prolongs the half-life of C-peptide in circulation, producing higher measured values that may not reflect greater insulin secretion. This confounder is particularly important in older adults and individuals with chronic kidney disease.
• Recent food intake — raises levels: Even a small meal will stimulate insulin and C-peptide release. Fasting C-peptide measurements require strict adherence to an 8-to-12-hour fast for valid comparison against reference intervals.
• Obesity — raises levels: Adiposity increases peripheral insulin resistance, driving compensatory beta cell hypersecretion. Elevated C-peptide in overweight individuals may reflect metabolic stress rather than a pathological condition.
• Exogenous insulin use — does not affect C-peptide directly: Injected insulin contains no C-peptide and does not suppress endogenous C-peptide in a straightforward way, though chronic exogenous insulin can suppress endogenous insulin release via negative feedback. This context must be considered when interpreting results in insulin-treated patients.
• Age — modest effect: C-peptide tends to rise modestly with age in healthy adults, partially reflecting age-associated increases in adiposity and decreased insulin sensitivity. Age-specific reference ranges are not universally established.
• Assay platform — affects absolute values: Kabytaev and colleagues, writing in Diabetes, Obesity and Metabolism in 2026, emphasize the need for C-peptide assay standardization, noting that absolute values can vary between platforms. Serial measurements should ideally use the same assay and laboratory for valid longitudinal comparison.
• Pregnancy — raises levels: Pregnancy increases insulin demand; fasting C-peptide rises during pregnancy as part of the normal physiological adaptation to gestational metabolic demands.

How C-Peptide Testing Works

What type of sample is used

Standard C-peptide testing uses a fasting venous blood draw. The sample is processed as serum. C-peptide in serum is stable at room temperature for several hours, but samples should be processed promptly or refrigerated to avoid degradation. A non-invasive alternative — the urine C-peptide creatinine ratio (UCPCR) — has been validated as a clinically useful substitute for serum C-peptide in stable outpatients and avoids the need for a blood draw. Wang and colleagues, publishing in Journal of Diabetes Research in 2019, documented the clinical implications of UCPCR across different diabetes types, confirming it as a practical and reproducible option in appropriate settings.

Fasting requirements

An 8-to-12-hour fast is standard for fasting serum C-peptide. Stimulated C-peptide tests — glucagon stimulation or mixed-meal tolerance test — require provider administration and involve a standardized insulin secretory challenge. These cannot be done independently. The choice between fasting and stimulated testing depends on the clinical question: fasting values are used for diabetes classification; stimulated peak values are more informative for assessing residual beta cell capacity in established diabetes.

Timing and turnaround

Serum C-peptide results are typically available within 24 to 48 hours at most clinical laboratories. The time of day of the blood draw can influence results modestly, since cortisol and other counter-regulatory hormones vary diurnally — morning fasting is the standard timing for reproducible baseline measurements. Specimen stability is important: samples should be processed or refrigerated within two hours of collection.

Fasting versus stimulated C-peptide: when each is ordered

A fasting serum C-peptide is the standard first-line measurement for diabetes classification and initial metabolic assessment. A stimulated C-peptide — using either 1 mg intravenous glucagon or a standardized mixed-meal load — produces a peak value that more fully reveals the beta cell's maximum secretory capacity. Jones and Hattersley, in their 2013 paper in Diabetic Medicine, describe how fasting C-peptide alone may misclassify some patients with partial beta cell function, particularly those with early or slowly progressive Type 1 diabetes. In clinical practice, stimulated testing is typically reserved for situations where the fasting result is ambiguous or where quantifying residual beta cell function matters for a specific decision, such as determining eligibility for an islet-preservation intervention.

Which Biomarkers Are Worth Testing Alongside C-Peptide

C-peptide provides a direct window into endogenous insulin secretion, but it rarely tells the full metabolic story on its own. Pairing it with adjacent markers provides a far more complete picture of beta cell function and overall metabolic health.

• Insulin (fasting): Measured alongside C-peptide, fasting insulin reflects peripheral insulin demand and sensitivity. The ratio of C-peptide to insulin can reveal hepatic insulin extraction efficiency. Why test alongside C-peptide: Together, these two markers distinguish insulin secretion from insulin resistance more precisely than either alone.
• Glucose (fasting): Fasting blood glucose provides the metabolic context for interpreting any C-peptide value. High C-peptide with high glucose suggests insulin resistance; low C-peptide with high glucose suggests insulin deficiency. Why test alongside C-peptide: C-peptide without glucose context is clinically incomplete.
• Hemoglobin A1c (HbA1c): HbA1c reflects average blood glucose over approximately 3 months. Carr and colleagues, writing in the Journal of the Endocrine Society in 2021, showed that peak C-peptide at diagnosis predicts subsequent glycemic control in Type 1 diabetes. Why test alongside C-peptide: Together they distinguish between inadequate insulin secretion and poor glycemic control from other causes.
• hs-CRP: High-sensitivity C-reactive protein reflects systemic low-grade inflammation, which is both a driver and a consequence of insulin resistance. Why test alongside C-peptide: Elevated hs-CRP in the context of elevated C-peptide supports an insulin resistance picture rather than primary beta cell dysfunction.
• Autoantibodies (GAD65, IA-2, ZnT8): In cases of ambiguous diabetes type, autoantibody testing alongside C-peptide distinguishes autoimmune beta cell destruction (Type 1 or LADA) from non-autoimmune insulin deficiency. Why test alongside C-peptide: Maddaloni and colleagues in 2022 confirmed that C-peptide combined with autoantibody testing improves diagnostic accuracy in distinguishing Type 1 from Type 2 diabetes.

When to Take This Seriously

A C-peptide result outside the reference range is not a diagnosis. It is a signal that warrants interpretation in clinical context. Several patterns are worth prompt discussion with a provider.

A very low or undetectable fasting C-peptide (below 0.2 nmol/L) in a person who has not yet been classified as Type 1 diabetic suggests significant beta cell loss and warrants autoantibody testing and clinical evaluation. Lachin and colleagues, writing in Diabetes in 2014, demonstrated that even low residual C-peptide in established Type 1 diabetes is associated with better glycemic control and fewer microvascular complications, underscoring the clinical value of measuring it rather than assuming it is absent.

High C-peptide in the context of unexplained low blood glucose warrants evaluation for insulinoma or sulfonylurea-related hyperinsulinism. Volpe and colleagues, writing in Diabetes, Metabolic Syndrome and Obesity in 2021, describe how C-peptide testing helps reduce inappropriate insulin prescribing by accurately characterizing whether beta cell function is retained or lost.

For individuals with borderline metabolic findings — elevated fasting glucose or HbA1c without a clear diabetes diagnosis — an elevated fasting C-peptide alongside elevated insulin and glucose is worth discussing with a provider as part of a broader metabolic workup. Kabytaev and colleagues in 2026 emphasize C-peptide's expanding role as a management biomarker beyond its traditional use in diabetes classification alone.

IMPORTANT SAFETY INFORMATION

This article is for educational and informational purposes only. C-peptide measurement is a clinical laboratory test that requires interpretation by a qualified healthcare provider in the context of your individual health history, symptoms, and other test findings. This content does not constitute medical advice, diagnosis, or treatment recommendations.

C-peptide reference ranges vary by laboratory and assay platform. The values presented in this article represent commonly cited population-derived reference intervals and are not universal diagnostic thresholds. Standardization of C-peptide measurement is an active area of ongoing work, as described by Kabytaev and colleagues in Diabetes, Obesity and Metabolism in 2026. Your provider will interpret your specific result in context.

This content does not replace consultation with a qualified clinician who can evaluate your individual health history, current medications, and clinical picture.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. C-peptide testing requires interpretation by a qualified healthcare provider in the context of your individual clinical history and other laboratory findings.